Nephrotoxicity of immunosuppressive drugsexperimental and clinical observations

Seminars in Nephrology

Volumn 17, Issue 1, 1997, Pages 34-45

  Andoh, Takeshi F ^a   Burdmann, Emmanuel A ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

ARTERY DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; DRUG INDUCED DISEASE; GLOMERULUS FILTRATION RATE; HEART TRANSPLANTATION; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE; ORGAN TRANSPLANTATION;

EID: 0031012546     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (128)

1. Terasaki PI, Park MS, Danovitch GM: Histocompatibility testing, crossmatching, and allocation of cadaveric kidney transplants, in Danovitch GM (ed): Handbook of Kidney Transplantation. Boston, MA, Little, Brown and Co, 1992, pp 43-66
2. Dunn J, Golden D, Van Buren CT, et al: Causes of graft loss beyond two years in the cyclosporine era. Transplantation 49:349-353, 1990
3. Bennett WM: The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43:S3-S7, 1995
4. Terasaki PI, Cecka JM, Cho Y: Overview, in Terasaki PI (ed): Clinical Transplants 1990. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1990
5. Opelz G, Schwarz V, Engelmann A, et al: Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients. Transplant Proc 23:373-375, 1991
6. Modena FM, Hosteller TH, Salahudeen AK, et al: Progression of kidney disease in chronic renal transplant rejection. Transplantation 52:239-244, 1991
7. Remuzzi G, Perico N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 48:S70-S74, 1995
8. English J, Evan A, Houghton DC, et al: Cyclosporineinduced acute renal dysfunction in the rat: Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44:135-141, 1987
9. Skorecki KL, Rutledge WP, Schrier RW: Acute cyclosporine nephrotoxicity-Prototype for a renal membrane signalling disorder. Kidney Int 42:1-10, 1992
10. Perico N, Ruggenenti P, Gaspari F, et al: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54:56-60, 1992
11. Conger JD, Kim GE, Robinette JB: Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 267:F443-F449, 1994
12. Bobadilla NA, Tapia E, Franco M, L et al: Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 46:773-779, 1994
13. Gallego MJ, Garcia Villalon AL, Lopez Farre AJ, et al: Mechanisms of the endothelial toxicity of cyclosporin A. Role of nitric oxide, cGMP, and Ca2+. Circ Res 74:477-484, 1994
14. Bunchman TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88:310-314, 1991
15. Curtis JJ, Luke RG, Dubovsky E, et al: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 2:477-479, 1986
16. Mihatsch MJ, Ryffel B, Gudat F: The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 48:S63-S69, 1995
17. Mihatsch MJ, Steiner K, Abeywickrama KH, et al: Risk factors for the development of chronic cyclosporinenephrotoxicity. Clin Nephrol 29:165-175, 1988
18. Lewis RM: Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int 48:S75-S78, 1995
19. Brenner BM, Cohen RA, Milford EL: In renal transplantation, one size may not fit all. J Am Soc Nephrol 3:162169, 1992
20. Wolfe JA, McCann RL, Sanfilippo F: Cyclosporineassociated microangiopathy in renal transplantation: A severe but potentially reversible form of early graft injury. Transplantation 41:541-544, 1986
21. Van Buren D, Van Buren CT, Flechner SM, et al: De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98:5462, 1985
22. Myers BD, Ross J, Newton L, et al: Cyclosporineassociated chronic nephropathy. N Engl J Med 311:699-705, 1984
23. Myers BD, Sibley R, Newton L, et al: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33:590-600, 1988
24. Myers BD, Newton L, Boshkos C, et al: Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 46:694-703, 1988
25. Myers BD, Newton L: Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 2:S45-S52, 1991
26. Zietse R, Balk AH, v.d.Dorpel MA, et al: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 14:1-5, 1994
27. Greenberg A, Thompson ME, Griffith BJ, et al: Cyclosporine nephrotoxicity in cardiac allograft patientsA seven-year follow-up. Transplantation 50:589-593, 1990
28. Greenberg A, Egel JW, Thompson ME, et al: Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am J Kidney Dis 9:12-22, 1987
29. Falkenhain ME, Cosio FG: Cyclosporine (CsA) causes progressive glomerular sclerosis (GS) and arteriolar hyalinosis (AH) in kidneys of heart (HTx) and liver (LTx) transplant recipients. J Am Soc Nephrol 5:1003, 1994 (abstr)
30. Bertani T, Ferrazzi P, Schieppati A, et al: Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 40:243-250, 1991
31. Jacobson SH, Jaremko G, Duraj FF, et al: Renal fibrosis in cyclosporine A treated renal allograft recipients: Morphological findings in relation to renal hemodynamics. Transplant Int 9:492-498, 1996
32. Ruiz P, Kolbeck PC, Scroggs MW, et al: Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation 45:91-95, 1988
33. Klintmalm G, Sundelin B, Bohman SO, et al: Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: Beneficial effect of low doses in early post-transplantation period. Lancet 2:950-954, 1984
34. Sommer BG, Innes JT, Whitehurst RM, et al: Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg 149:756-764, 1985
35. Mourad G, Vela C, Ribstein J, Mimran A: Chronic cyclosporine nephrotoxicity is reversible in renal transplant recipients. Nephrol Dial Transplant 8:1045, 1993 (abstr)
36. Morozumi K, Thiel G, Albert FW, et al: Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 38:1-8, 1992
37. Palestine AG, Austin HAI, Balow JE, et al: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314:1293-1298, 1986
38. Austin HAI, Palestine AG, Sabnis SG, et al: Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis. Am J Nephrol 9:392-402, 1989
39. Deray G, Benhmida M, Le Hoang P, et al: Renal function and blood pressure in patients receiving long-term, lowdose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 117:578-583, 1992
40. Andersen CB, Larsen S, Elmgreen J, et al: Cyclosporine-induced renal morphologic and immunohistologic changes in patients with chronic uveitis. APMIS 99:576582, 1991
41. Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654-1660, 1992
42. Fioretto P, Steffes MW, Mihatsch MJ, et al: Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 48:489-495, 1995
43. Powles AV, Cook T, Hulme B, et al: Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 128:159-165, 1993
44. Svarstad E, Heiland S, Morken T, et al: Renal effects of maintenance low-dose cyclosporin A treatment in psoriasis. Nephrol Dial Transplant 9:1462-1467, 1994
45. Pei Y, Scholey JW, Katz A, et al: Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis 23:528-536, 1994
46. Messana JM, Johnson KJ, Mihatsch MJ: Renal structure and function effects after low dose cyclosporine in psori-. asis patients: A preliminary report. Clin Nephrol 43:150-153, 1995
47. Zachariae H, Hansen HE, Kragballe K, et al: Morphologie renal changes during cyclosporine treatment of psoriasis: Studies on pretreatment and posttreatment kidney biopsy specimens. J Am Acad Dermatol 26:415-419, 1992
48. Zachariae H, Olsen TS: Efficacy of cyclosporin A (CyA) in psoriasis: An overview of dose/response, indications, contraindications and side-effects. Clin Nephrol 43:154-158, 1995
49. Young EW, Ellis CN, Messana JM, et al: A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 46:1216-1222, 1994
50. Edwards BD, Chalmers RJG, O'Driscoll JB, et al: Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin Nephrol 41:350-356, 1994
51. Sowden JM, Berth-Jones J, Ross JS, et al: Doubleblind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 338:137-140, 1991
52. The Multiple Sclerosis Study Group: Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neural 27:591-605, 1990
53. Sund S, Foire O, Berg KJ, et al: Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol 41:33-40, 1994
54. Mihatsch MJ, Hovig T, Lemoine R, et al: Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients. Br J Rheumatol 32:65-71, 1993
55. Madhok R, Torley HI, Capell HA: A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 18:1485-1489, 1991
56. Ahern MJ, Harrison W, Hollingsworth P, et al: A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust N Z J Med 21:844849, 1991
57. Landewe RBM, Goei The HS, van Rijthoven AWAM, et al: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637-643, 1994
58. Ludvvin D, Alexopoulou I: Cyclosporin A nephropathy in patients with rheumatoid arthritis. Br J Rheumatol 32:60-64, 1993
59. Cohen DJ, Appel GB: Cyclosporine: Nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis. Semin Arthritis Rheum 21:43-48, 1992
60. Landewe RBM, Dijkmans BAC, van der Woude FJ, et al: Longterm low dose cyclosporine in patients with rheumatoid arthritis: Renal function loss without structural nephropathy. J Rheumatol 23:61-64, 1996
61. Clements PJ, Lachenbruch PA, Sterz M, et al: Cyclosporine in systemic sclerosis: Results of a forty-eightweek open safety study in ten patients. Arthritis Rheum 36:75-83, 1993
62. Wiesner RH, Ludwig J, Lindor KD, et al: A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 322:1419-1424, 1990
63. Lombard M, Portmann B, Neuberger J, et al: Cyclosporin A treatment in primary biliary cirrhosis: Results of a long-term placebo controlled trial. Gastroenterology 104:519-526, 1993
64. Kolkin S, Nahman NSJ, Mendell JR: Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 37:147-149, 1987
65. Hannedouche TP, Delgado AG, Gnionsahe AD, et al: Nephrotoxicity of cyclosporine in autoimmune diseases. Adv Nephrol 19:169-186, 1990
66. Tindall RSA, Rollins JA, Phillips JT, et al: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719-724, 1987
67. Lafayette RA, Mayer G, Meyer TW: The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 3:1892-1899, 1993
68. Stahl RAK, Adler S, Baker PJ, et al: Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial cells in culture. Kidney Int 35:1161-1167, 1989
69. Lanese DM, Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 91:2144-2149, 1993
70. Auch-Schwelk W, Duske E, Hink U, et al: Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension 23:832-837, 1994
71. Marumo T, Nakaki T, Hishikawa K, et al: Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 25:764-768, 1995
72. Kon V, Hunley TE, Fogo A: Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 60:8995, 1995
73. Bokemeyer D, Kramer HJ, Meyer-Lehnert H: Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle. Hypertension 21:166-172, 1993
74. Takenaka T, Hashimoto Y, Epstein M: Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. J Am Soc Nephrol 3:42-50, 1992
75. Shehata M, el Nahas AM, Barkworth E, et al: Increased platelet-derived growth factor in the kidneys of cyclosporin-treated rats. Kidney Int 46:726-732, 1994
76. Rossi NF, Churchill PC, McDonald FD, et al: Mechanism of cyclosporin A-induced renal vasoconstriction in the rat. J Pharmacol Exp Ther 250:896-901, 1989
77. Gallego MJ, Lopez Faire A, Riesco A, et al: Blockade of endothelium-dependent responses in conscious rats by cyclosporin A: Effect of L-arginine. Am J Physiol 264:H708H714, 1993
78. De Nicola L, Thomson SC, Wead LM, et al: Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92:1859-1865, 1993
79. Martin M, Neumann D, Hoff T, et al: Interleukin-1induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 45:150-158, 1994
80. Luscher TF, Wenzel RR: Endothelin in renal disease: Role of endothelin antagonists. Nephrol Dial Transplant 10:162-166, 1995
81. Ghiggeri GM, Altieri P, Oleggini R, et al: Selective enhancement by cyclosporin A of collagen expression by mesangial cells "in culture". Eur J Pharmacol 270:195-201, 1994
82. Wolf G, Neilson EG: Increases in levels of collagen types I and IV messenger ribonucleic acid in murine kidneys after treatment with ciclosporin. Nephron 60:87-91, 1992
83. Rosen S, Greenfeld Z, Brezis M: Chronic cyclosporine-induccd nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 49:445-452, 1990
84. Elzinga LW, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol 4:214-221, 1993
85. Mason J, Muller-Schweinitzer E, Dupont M, et al: Cyclosporine and the renin-angiotensin system. Kidney Int 39:S28-S32, 1991
86. Burdmann EA, Andoh TF, Nast CC, et al: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269:F491-F499, 1995
87. Young BA, Burdmann EA, Johnson RJ, et al: Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 48:431-438, 1995
88. Young BA, Burdmann EA, Johnson RJ, et al: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439-448, 1995
89. Jackson NM, O'Connor RP, Humes HD: Interactions of cyclosporine with renal proximal tubule cells and cellular membranes. Transplantation 46:109-114, 1988
90. Rogers TS, Elzinga L, Bennett WM, et al: Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity. Dietary protection by fish oil. Transplantation 45:153-156, 1988
91. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540, 1993
92. Jackson NM, Hsu CH, Visscher GE, et al: Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. J Pharmacol Exp Ther 242:749-756, 1987
93. Tufro-McReddie A, Gomez RA, Norling LL, et al: Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney. Kidney Int 43:615622, 1993
94. Johnson RJ, Alpers CE, Yoshimura A, et al: Renal injury from angiotensin II-mediated hypertension. Hypertension 19:464-474, 1992
95. Meister B, Lippoldt A, Bunnemann B, et al: Cellular expression of angiotensin type-1 receptor mRNA in the kidney. Kidney Int 44:331-336, 1993
96. Gardiner DS, Watson MA, Junor BJR, et al: The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies. Nephrol Dial Transplant 6:363-367, 1991
97. Ahuja SS, Shrivastav S, Danielpour D, et al: Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 60:718-723, 1995
98. Shihab FS, Andoh TF, Tanner AM, et al: Role of transforming growth factor-β in experimental chronic cyclosporine nephropathy. Kidney Int 49:1141-1151, 1996
99. Shehata M, Cope GH, Johnson TS, et al: Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 48:1487-1496, 1995
100. Khanna A, Li B, Sehajpal PK, et al: Mechanism of action of cyclosporine: A new hypothesis implicating transforming growth factor-β. Transplant Rev 9:41-48, 1995
101. Sawada S, Suzuku G, Kawase Y, et al: Novel immunosuppressive agent, FK506: In vitro effects on the cloned T cell activation. J Immunol 139:1797-1803, 1987
102. Kino T, Inamura N, Sakai F, et al: Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 19:36-39, 1987 (suppl 6)
103. Harding MW, Galat A, Uehling DE, et al: A receptor for the immunosuppressant FK506 is a cis-trans peptidylprolyl isomerase. Nature 341:758-760, 1989
104. Tocci MJ, Matkovich DA, Collier KA, et al: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143:718-726, 1989
105. Starzl TE, Todo S, Fung J, et al: FK 506 for liver, kidney, and pancreas transplantation. Lancet 2:1000-1004, 1989
106. Todo S, Fung JJ, Starzl TE, et al: Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 212:295-305, 1990
107. Armitage JM, Kormos RL, Monta S, et al: Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 54:205-210, 1992
108. Demetris AJ, Fung JJ, Todo S, et al: Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy-A clinicopathologic study of 96 patients. Transplantation 53:1056-1062, 1992
109. Klintmalm GB, Goldstein R, Gonwa T, et al: Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc 25:679-688, 1993
110. Jordan ML, Shapiro R, Vivas ÇA, et al: FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 25:638-640, 1993
111. McCauley J: The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 2:662-669, 1993
112. Andoh TF, Burdmann EA, Lindsley J, et al: Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 57:483-489, 1994
113. Andoh TF, Burdmann EA, Lindsley J, et al: Functional and structural characteristics of experimental FK506 nephrotoxicity. Clin Exp Pharmacol Physiol 22:646-654, 1995
114. Mochizuki M, Masuda K, Sakane T, et al: A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115:763-769, 1993
115. Japanese Study of FK 506 on Kidney Transplantation: Results of late phase II study. Transplant Proc 25:649654, 1993
116. Klintmalm GB, Goldstein R, Gonvva T, et al: Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Transplant Proc 25:635-637, 1993
117. Thomson AW, Carroll PB, McCauley J, et al: FK 506: A novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol 14:323-344, 1993
118. Fung J, Abu Elmagd K, Jain A, et al: A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 23:29772983, 1991
119. Uemoto S, Tanaka K, Honda K, et al: Experience with FK506 in living-related liver transplantation. Transplantation 55:288-292, 1993
120. Shapiro R, Jordan M, Scantlebury V, et al: FK 506 in clinical kidney transplantation. Transplant Proc 23:30653067, 1991
121. Fung JJ, Alessiani M, Abu Elmagd K, et al: Adverse effects associated with the use of FK506. Transplant Proc 23:3105-3108, 1991
122. Randhawa PS, Shapiro R, Jordan ML, et al: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 17:60-68, 1993
123. Myers BD, Sibley R, Newton L, et al: The longterm course of cyclosporine-associated chronic nephropathy. Kidney Int 33:590-600, 1988
124. Liu J, Farmer JDJ, Lane WS, et al: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBPFK506 complexes. Cell 66:807-815, 1991
125. Sehgal SN, Molnar-Kimber K, Ocain TD, et al: Rapamycin: A novel immunosuppressive macrolide. Med Res Rev 14:1, 1994 (review)
126. Tu Y, Stepkowski SM, Chou TC, et al: The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 59:177, 1995
127. Martin DF, DeBarge LR, Nussenblatt RB, et al: Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 154:922, 1995
128. DiJoseph JF, Sharma RN, Chang JY: The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 53:507, 1992